Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | PGK2 | P07205 | 1/20 | 0.44 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945820 | 0.89 | PGK1 (0.37) | PGK1PGK2SLC11A2CYP3A4TSHR | |
| SCHEMBL13306021 | 0.88 | PGK1 (0.38) | PGK1PGK2SLC11A2 | |
| SCHEMBL29126141 | 0.83 | CA1 (0.39) | PGK1PGK2SLC11A2CYP3A4TSHR | |
| SCHEMBL11217789 | 0.82 | CYP3A4 (0.35) | PGK1PGK2SLC11A2CYP3A4TSHR | |
| SCHEMBL28337198 | 0.78 | CYP3A4 (0.39) | PGK1PGK2SLC11A2CYP3A4TSHR | |
| SCHEMBL11416603 | 0.77 | — | — | |
| SCHEMBL258395 | 0.77 | — | — | |
| SCHEMBL893003 | 0.77 | ALDH1A1 (0.41) | PGK1PGK2CYP3A4TSHRHTR1D | |
| SCHEMBL585059 | 0.77 | HRH3 (0.40) | TSHRMAPK1HTR1D | |
| SCHEMBL18280483 | 0.76 | CYP3A4 (0.41) | PGK1PGK2CYP3A4MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060915-A2 | DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME | Mologic Limited (GB) | 2016-08-31 | — | — | EP | claimed |
| WO-2015059487-A2 | DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME | MOLOGIC LIMITED (GB) | 2015-04-30 | — | — | WO | claimed |
| US-12320804-B2 | Detection of cleavage activity of an enzyme | MOLOGIC LIMITED (GB) | 2025-06-03 | — | — | US | disclosed |
| US-20250157661-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| WO-2025094673-A1 | VINYL COMPOUND, VINYL COMPOSITION, VINYL RESIN CURED PRODUCT, PREPREG, FILM WITH RESIN, METAL FOIL WITH RESIN, METAL-CLAD LAMINATE, AND PRINTED WIRING BOARD | 住友化学株式会社 | 2025-05-08 | — | — | WO | disclosed |
| US-11953506-B2 | Monitoring inflammation status | MOLOGIC LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-3928100-B1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-20220120760-A1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| US-20220120760-A1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3928100-A1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | Mologic Limited (GB) | 2021-12-29 | — | — | EP | disclosed |
| US-10866236-B2 | Detection of cleavage activity of an enzyme | MOLOGIC LIMITED (GB) | 2020-12-15 | — | — | US | disclosed |
| US-20070032578-A1 | Curable liquid compositions containing bisoxazoline | HENKEL KGAA (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032578-A1 | Curable liquid compositions containing bisoxazoline | HENKEL KGAA (DE) | 2007-02-08 | — | — | US | disclosed |
| EP-1730117-A2 | THIOUREA COMPOSITIONS AND USES THEREOF | The University of Hong Kong (CN) | 2006-12-13 | — | — | EP | disclosed |
| EP-1716215-A1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | National Starch and Chemical Investment Holding Corporation (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005091697-A2 | THIOUREA COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215783-A1 | Thiourea compositions and uses thereof | UNIVERSITY OF HONG KONG, THE (HK) | 2005-09-29 | — | — | US | disclosed |
| WO-2005085384-A1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING COPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-6252009-B1 | CROSSLINKING ACRYLONITRILE WITH DIISOCYANATE | THE GOODYEAR TIRE & RUBBER COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0903338-A2 | Synthesis of stable nitrile oxide compounds | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215783-A1 | Thiourea compositions and uses thereof | DDT, ITK, DTYMK | PGK1 681/4885PGK2 733/4885SLC11A2 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.